Diamyd Medical
17,92
SEK
-3,03 %
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Mindre end 1K følgere
-3,03%
+9%
+19,15%
+28,92%
+28,37%
+152,75%
+16,76%
-12,81%
+494,03%
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Læs mereMarkedsværdi
1,87 mia. SEK
Aktieomsætning
3,78 mio. SEK
Omsætning
130 t
EBIT %
-112.746,15 %
P/E
-
Udbytteafkast, %
-
Finanskalender
29.1
2025
Delårsrapport Q1'25
9.4
2025
Delårsrapport Q2'25
25.6
2025
Delårsrapport Q3'25
ViserAlle indholdstyper
Diamyd Medical AB: Renowned Diabetes Investigator, Emily Sims, Joins Diamyd Medical's Scientific Advisory Board
Diamyd Medical AB: Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools